Metraipolis › archive › dc_969f39bc0798
Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study — Europe PMC PMID:42382757
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42382757
- DOI
- 10.3389/fimmu.2026.1809094
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-19T09:26:20.418Z
- SHA-256 of the archived text
4bfaf3d5d0e13efb16d6e249d4a76171d3a2eb72b45f660c68ffee8550fd6237- Stable URL of this page
https://metraipolis.com/documento/dc_969f39bc0798
How to cite
Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study — Europe PMC PMID:42382757 — Europe PMC (en), https://europepmc.org/article/MED/42382757 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_969f39bc0798 (Metraipolis archive dc_969f39bc0798, sha256 4bfaf3d5d0e13efb16d6e249d4a76171d3a2eb72b45f660c68ffee8550fd6237)
BibTeX
@misc{dc969f39bc0798,
title = {Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study — Europe PMC PMID:42382757},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42382757},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_969f39bc0798; sha256 4bfaf3d5d0e13efb16d6e249d4a76171d3a2eb72b45f660c68ffee8550fd6237},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42382757. Agents can read the archived copy with the MCP tool read_document.